Structure-activity relationships of synthetic coumarins as HIV-1 inhibitors

被引:141
作者
Kostova, I.
Raleva, S.
Genova, P.
Argirova, R.
机构
[1] Med Univ, Fac Pharm, Dept Chem, Sofia 1000, Bulgaria
[2] Natl Ctr Infect & Parasit Dis, Dept Virol, Sofia 1233, Bulgaria
关键词
D O I
10.1155/BCA/2006/68274
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HIV/AIDS pandemics is a serious threat to health and development of mankind, and searching for effective anti-HIV agents remains actual. Considerable progress has been made in recent years in the field of drug development against HIV. A lot of structurally different coumarins were found to display potent anti-HIV activity. The current review demonstrates the variety of synthetic coumarins having unique mechanism of action referring to the different stages of HIV replication. Recent studies based on the account of various synthetic coumarins seem to indicate that some of them serve as potent non-nucleoside RT-inhibitors, another as inhibitors of HIV-integrase or HIV-protease. The merits of selecting potential anti-HIV agents to be used in rational combination drugs design and structure-activity relationships are discussed. The scientific community is looking actively for new drugs and combinations for treatment of HIV infection effective for first-line treatment, as well as against resistant mutants. The investigation on chemical anti-HIV agents gives hope and optimism about it. This review article describes recent progress in the discovery, structure modification, and structure-activity relationship studies of potent anti-HIV coumarin derivatives. Copyright (C) 2006 I. Kostova et al.
引用
收藏
页数:9
相关论文
共 39 条
[1]  
BOURINBAIAR AS, 1993, ACTA VIROL, V37, P241
[2]   RESOLUTION AND COMPARATIVE ANTI-HIV EVALUATION OF THE ENANTIOMERS OF CALANOLIDE-A AND CALANOLIDE-B [J].
CARDELLINA, JH ;
BOKESCH, HR ;
MCKEE, TC ;
BOYD, MR .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (09) :1011-1014
[3]   TOTAL SYNTHESIS OF (PLUS-OR-MINUS)-CALANOLIDE-A, A NON-NUCLEOSIDE INHIBITOR OF HIV-1 REVERSE-TRANSCRIPTASE [J].
CHENERA, B ;
WEST, ML ;
FINKELSTEIN, JA ;
DREYER, GB .
JOURNAL OF ORGANIC CHEMISTRY, 1993, 58 (21) :5605-5606
[4]   Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects [J].
Creagh, T ;
Ruckle, JL ;
Tolbert, DT ;
Giltner, J ;
Eiznhamer, DA ;
Dutta, B ;
Flavin, MT ;
Xu, ZQ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (05) :1379-1386
[5]   SYNTHESIS OF OPTICALLY-ACTIVE CALANOLIDE-A AND CALANOLIDE-B [J].
DESHPANDE, PP ;
TAGLIAFERRI, F ;
VICTORY, SF ;
YAN, SJ ;
BAKER, DC .
JOURNAL OF ORGANIC CHEMISTRY, 1995, 60 (10) :2964-2965
[6]   Synthesis and biological evaluation of certain α,β-unsaturated ketones and their corresponding fused pyridines as antiviral and cytotoxic agents [J].
El-Subbagh, HI ;
Abu-Zaid, SM ;
Mahran, MA ;
Badria, FA ;
Al-Obaid, AM .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) :2915-2921
[7]   Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers [J].
Flavin, MT ;
Rizzo, JD ;
Khilevich, A ;
Kucherenko, A ;
Sheinkman, AK ;
Vilaychack, V ;
Lin, L ;
Chen, W ;
Greenwood, EM ;
Pengsuparp, T ;
Pezzuto, JM ;
Hughes, SH ;
Flavin, TM ;
Cibulski, M ;
Boulanger, WA ;
Shone, RL ;
Xu, ZQ .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (06) :1303-1313
[8]  
Gaddam S, 1997, J LABELLED COMPD RAD, V39, P901, DOI 10.1002/(SICI)1099-1344(199711)39:11<901::AID-JLCR39>3.0.CO
[9]  
2-H
[10]   HIV-inhibitory natural products .30. Structure-activity modifications of the HIV-1 inhibitors (+)-calanolide A and (-)-calanolide B [J].
Galinis, DL ;
Fuller, RW ;
McKee, TC ;
Cardellina, JH ;
Gulakowski, RJ ;
McMahon, JB ;
Boyd, MR .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (22) :4507-4510